Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) has issued an update.
OncoSil Medical Limited has announced the joint appointment of Mr. Tim Luscombe and Mr. David Wood as Joint Company Secretaries, effective September 1, 2025. This change follows the resignation of Ms. Olga Smejkalova. The new appointees are part of Bio101 Financial Advisory, bringing expertise in financial management and corporate governance to the company. This strategic move is expected to enhance OncoSil’s operational efficiency and strengthen its governance framework, potentially impacting its industry positioning positively.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a global medical device company specializing in Interventional Oncology. The company focuses on improving cancer treatment outcomes through the intratumoural placement of Phosphorous-32 Microparticles, particularly for unresectable locally advanced pancreatic cancer. OncoSil’s targeted approach allows for higher radiation doses directly into tumors, minimizing damage to surrounding organs. The OncoSil™ device has received CE Marking approval and is recognized as a breakthrough device in Europe and the United States, with sales approved in over 30 countries.
Average Trading Volume: 41,350
Technical Sentiment Signal: Sell
Current Market Cap: A$21.55M
Learn more about OSL stock on TipRanks’ Stock Analysis page.